Concepedia

Yoshiko Kagoshima

YK

Statistics

Publications

7

Citations

264

H-Index

7

Active since

2008

Affiliations

Daiichi-Sankyo (Japan)(Current)

Daiichi Sankyo (Germany)

The University of Tokyo

Yoshiko Kagoshima is an author at Daiichi-Sankyo (Japan) specializing in drug discovery, pharmacology, and medicinal chemistry.

Publications per year

2008–2023

7

Publications

7

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

Ryohei Katayama, Bo Gong, Noriko Togashi et al. · Nature Communications · 2019 · 141 citations · Full text

, , +15

A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1

Masashi Numata, Noriyasu Haginoya, Machiko Shiroishi et al. · Cancer Cell International · 2023 · 29 citations · Full text

, , +13

Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor

Ryutaro Kanada, Yoshiko Kagoshima, Takashi Suzuki et al. · Journal of Medicinal Chemistry · 2022 · 25 citations · Full text

, , +13

Amide analogs of antifungal dioxane–triazole derivatives: Synthesis and in vitro activities

Takuya Uchida, Yoshiko Kagoshima, Toshiyuki Konosu · Bioorganic & Medicinal Chemistry Letters · 2009 · 20 citations

, , +13

Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring

Ryutaro Kanada, Yoshiko Kagoshima, Masayoshi Asano et al. · Bioorganic & Medicinal Chemistry Letters · 2022 · 19 citations · Full text

, , +16

1–5 of 7